Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Completed

• Conditions: Central Serous Chorioretinopathy

• Registration Number: NCT05847049
• Lead Sponsor: Dar El Oyoun Hospital

Brief Summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Detailed Description

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.

Investigators collected and recorded the following data:

* Age

* Gender

* Systemic hypertension (present or not)

* Smoking (Yes / No)

* Best corrected visual acuity (BCVA) (baseline, final)

* Central macular thickness (CMT) (baseline, final)

* Serous detachment Height (SDH) (baseline, final)

* Duration of Follow-up ( in months)

Study Timeline

• Study Start: 2023-02-28
• Primary Completion: 2023-03-25
• Status Verified: 2023-04
• Study First Submitted: 2023-04-05
• Study Completion: 2023-04-06
• Study First Submitted QC: 2023-05-05
• Last Update Submitted: 2023-05-05
• Study First Posted: 2023-05-06
• Last Update Posted: 2023-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion Criteria

• • CSCR treated by other modalities

  • CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in central macular thickness (CMT ) in microns	(baseline, 6 months)	reduction in CMT after therapy
Change in serous detachment height (SDH) in microns	(baseline, 6 months)	reduction in SDH after therapy

Secondary Outcome Measures

Name	Time	Method
Duration of Follow-up ( in months)	(baseline, 6 months)	Duration of Follow-up ( in months)
Change in BCVA	(baseline, 6 months)	number of lines of improvement in BCVA after therapy
Complications (Eplerenone, Aflibercept, and nepafenac)	(baseline, 6 months)	present or absent

Trial Locations

Locations (1)

Kasr alainy faculty of medicine; 🇪🇬 Cairo, Egypt